-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
About 10%-30% of patients with classic Hodgkin lymphoma (cHL) are refractory to initial treatment or relapse after standard treatment
Lymphoma stem cells
Phase 1-2 studies evaluated the combination of Bentuximab (BV) and Nivolumab (Nivo) as the primary rescue therapy for patients with relapsed/refractory (r/r) classic Hodgkin lymphoma (cHL) Effectiveness and safety
In the first and second parts, BV and Nivo are staggered in the first cycle, and BV and Nivo are given on the same day in the 2-4 cycle
PFS and OS
PFS and OSThe objective response rate (ORR; n=91) was 85%, and 67% of patients achieved complete remission (CR)
The objective response rate (ORR; n=91) was 85%, of which 67% of patients achieved complete remission (CR), and the objective response rate (ORR; n=91) was 85%, of which 67% of patients achieved complete remission ( At a median follow-up of 34.
immunity
The results of the study showed that the long-term follow-up of BV and Nivo as the primary rescue program showed long-lasting efficacy and excellent progression-free survival (PFS), especially in patients who underwent transplantation directly after the end of the study treatment, and there was no additional Toxic reaction
The long-term follow-up of BV and Nivo as the primary rescue plan showed long-lasting efficacy and excellent progression-free survival (PFS), especially in patients who underwent transplantation directly after the end of the study treatment, and there was no additional toxicity.
Original source:
Ranjana H.
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
in this message
